R. Ross MacLean

Apr 16, 2024 | bpspubs.onlinelibrary.wiley.com | Jeremy Weleff |Julio C Nunes |Mehmet Sofuoglu |R. Ross MacLean

CONFLICT OF INTEREST STATEMENT The authors disclose no conflicts of interest. J.P.D. has been supported in clinical trials by Jazz Pharmaceuticals, specifically through medication provisions. Additionally, J.P.D. has been a compensated consultant for Boehringer Ingelheim. REFERENCES 1, , . Drug overdose deaths in the United States, 2001-2021. NCHS Data Brief. 2022; 457: 1-8. 2. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy.

Mar 4, 2024 | bpspubs.onlinelibrary.wiley.com | R. Ross MacLean |Suzanne Spinola |Brian Pittman |Julia Meyerovich

DATA AVAILABILITY STATEMENT The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Nov 22, 2023 | bpspubs.onlinelibrary.wiley.com | Ajay Manhapra |R. Ross MacLean |Robert A. Rosenheck |William Becker

1 INTRODUCTION A re-examination of the clinical principles involved in the initiation, continuation and discontinuation of long-term opioid therapy (LTOT) for chronic pain is long overdue, especially in the context of an unrelenting opioid overdose crisis in the United States that is believed to have originated partly from excessive LTOT prescribing.